Peak Bio is a biopharmaceutical company that focuses on the drug development to treat Oncology and Inflammatory diseases.
Peak Bio has raised $25.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in April 2022.
Peak Bio's investors include Palo Alto Investors, Hoyoung Huh.
Peak Bio is headquartered in Palo Alto, United States.
Peak Bio is a biopharmaceutical company that focuses on the drug development to treat Oncology and Inflammatory diseases.
Peak Bio is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Peak Bio — Funding & Investors." VCBacked, April 28, 2022, https://www.vcbacked.co/company/peak-bio. Accessed September 30, 2026.
VCBacked. (2022). Peak Bio — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/peak-bio
{{cite web |title=Peak Bio — Funding & Investors |url=https://www.vcbacked.co/company/peak-bio |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated